This Kaplan-Mieir plot show the Castration - Resistant Prostate Cancer Free survival probability (%) vs time for two groups: (A) Darolutamide + ADT + Docetaxel, versus (B) Placebo + ADT + Docetaxel.
There is a very large increase in survival probability with the Darolutamide group (A) vs Placebo group (B).
The Cohort was High Risk men.
FDA Approves Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
What's different between Xtandi vs NUBEQA® (darolutamide) vs ERLEADA® (apalutamide)
Enzalutamide or Darolutamide
benefit of taking a break from Lupron and using darolutamide alone?
Another promising androgen blocker in clinical trials: Darolutamide (ODM-201) 
